SEC Filing Summary: Amedica Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amedica Corporation on December 14, 2015, regarding events occurring on December 11, 2015. The filing details material modifications to the rights of security holders through amendments to Series A and Series C Warrants issued in a September 2015 offering. The filing also discloses the entry into "Leak-Out Agreements" with investors to restrict share sales and prevent new equity financing for a specified period.
Key Financial Metrics and Capital Structure
- Recent Proceeds: The Company received approximately $5.0 million in gross proceeds in November 2015 from the automatic exercise of Series B Warrants, resulting in the issuance of 49,862,877 shares.
- Series A Warrants: Exercise price fixed at $0.0998 per share. The number of underlying shares was adjusted to 63.0 million following the Series B exercise. As of December 11, 2015, 13.1 million of these shares were registered for resale.
- Series C Warrants: Exercise price fixed at $0.10028 per share. The maximum number of shares issuable is capped at 16,404,200. Approximately 4.8 million shares were issued prior to the amendment.
- Liquidity and Debt: The filing text does not provide specific values for total cash, cash flow, operating margins, or outstanding debt.
Material Changes Versus Prior Period
- Price Fixation: Both Series A and Series C warrant exercise prices were fixed, removing provisions for further downward adjustments based on automatic exercises.
- Exercisability: Series A Warrants became immediately exercisable on December 11, 2015, rather than waiting six months post-issuance. Series C Warrants are no longer subject to automatic exercise and must be exercised by December 30, 2015, or they will terminate.
- Share Cap: A hard cap of 16.4 million shares was established for Series C Warrant issuances.
- Anti-Dilution Adjustment: For every share issued upon the exercise of a Series C Warrant, the number of shares underlying the corresponding Series A Warrant held by that investor will increase by one.
Guidance, Outlook, and Restrictions
- Leak-Out Agreements: Investors agreed not to sell shares between December 11 and December 15, 2015. From December 16 through January 15, 2016, sales are restricted to the greater of 200,000 shares or 15% of daily average trading volume, unless the stock price is at or above $0.20.
- Financing Moratorium: The Company agreed not to close any equity or equity-linked financing between December 11, 2015, and January 15, 2016.
- Cashless Exercise Limits: Series A Warrants allow cashless exercise, but if the shares are registered, the Volume Weighted Average Price (VWAP) used in the calculation cannot exceed $0.15.
- Outlook: The filing does not contain forward-looking financial guidance or management commentary regarding future operational performance.
Investor Verification Checklist
- Verify the current trading volume and price of Amedica common stock to assess the impact of the Leak-Out Agreement restrictions.
- Confirm the total number of outstanding Series A and Series C warrants and the potential dilution if exercised at the fixed prices of $0.0998 and $0.10028.
- Review the Company's cash position to determine if the $5.0 million from the Series B exercise is sufficient to fund operations until the January 15, 2016 financing moratorium expires.
- Monitor the December 30, 2015 deadline for Series C Warrant exercises to anticipate potential share issuance.